| abstract |
The present disclosure relates to formulations of proton pump inhibitors such as omeprazole or esomeprazole including their salts or hydrated salts, such as esomeprazole sodium, esomeprazole magnesium or esomeprazole magnesium dihydrate, and methods of use in treating ulcers in equines and other veterinary animals. The disclosure also relates to injectable formulations of proton pump inhibitors such as omeprazole or esomeprazole including their salts or hydrated salts, such as esomeprazole sodium, esomeprazole magnesium, or esomeprazole magnesium dihydrate, which have a small particle size, such as a median particle size of less than 10 µm or less than 5 µm. |